134 related articles for article (PubMed ID: 11305737)
1. Effect of intravenous iloprost and alprostadil (PGE1) on peripheral resistance during femoro-distal reconstructions.
Krueger U; Scholz H; Heise M; Adeberg P; Petzold M; Zanow J; Karrenberg R
Int Angiol; 2000 Dec; 19(4):358-65. PubMed ID: 11305737
[TBL] [Abstract][Full Text] [Related]
2. Iloprost reduces peripheral resistance during femoro-distal reconstruction.
Smith FC; Tsang GM; Watson HR; Shearman CP
Eur J Vasc Surg; 1992 Mar; 6(2):194-8. PubMed ID: 1374040
[TBL] [Abstract][Full Text] [Related]
3. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
Schellong S; Altmann E; von Bilderling P; Rudofsky G; Waldhausen P; Rogatti W
Prostaglandins Leukot Essent Fatty Acids; 2004 Jun; 70(6):503-9. PubMed ID: 15120713
[TBL] [Abstract][Full Text] [Related]
4. Decrease of peripheral resistance after intraoperative administration of iloprost in patients with and without type 2 diabetes mellitus and with peripheral arterial occlusive disease.
Hirsch K; Säemann M; Walter C; Taher F; Edda S; Mlekusch I; Jäger H; Assadian A; Falkensammer J
Diab Vasc Dis Res; 2020; 17(5):1479164120930589. PubMed ID: 32589047
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological manipulation of peripheral resistance during distal vascular reconstruction.
Smith FC; Shearman CP
Vasa Suppl; 1992; 36():55-7. PubMed ID: 1382323
[TBL] [Abstract][Full Text] [Related]
9. Effect of prostacyclin analogue iloprost on haemodynamic parameters during femoro-crural reconstruction.
Smith FC; Shearman CP
Agents Actions Suppl; 1992; 37():251-7. PubMed ID: 1378685
[TBL] [Abstract][Full Text] [Related]
10. The influence of intraarterial prostaglandin E(1) on vascular hydraulic impedance and infrainguinal graft patency.
Heise M; Krüger U; Pfitzmann R; Neuhaus P; Scholz H; Settmacher U
Eur J Vasc Endovasc Surg; 2001 Sep; 22(3):219-25. PubMed ID: 11506514
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant prostanoid treatment during femorodistal reconstruction.
Smith FC; Thomson IA; Hickey NC; Paterson IS; Tsang GM; Simms MH; Shearman CP
Ann Vasc Surg; 1993 Jan; 7(1):88-94. PubMed ID: 7686028
[TBL] [Abstract][Full Text] [Related]
12. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure.
Stanek B; Pacher R
Jpn Heart J; 1997 Jan; 38(1):53-65. PubMed ID: 9186281
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
Zhao L; Lu J; Wang C; Zhao W; Qing E; Ma J
J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1208-11. PubMed ID: 24090805
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
[TBL] [Abstract][Full Text] [Related]
15. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine.
Stanek B; Sturm B; Frey B; Hülsmann M; Bojic A; Berger R; Rödler S; Locker G; Grimm M; Laufer G; Pacher R
J Heart Lung Transplant; 1999 Apr; 18(4):358-66. PubMed ID: 10226901
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of pulmonary hypertension with aerosolized iloprost.
Machherndl S; Kneussl M; Baumgartner H; Schneider B; Petkov V; Schenk P; Lang IM
Eur Respir J; 2001 Jan; 17(1):8-13. PubMed ID: 11307761
[TBL] [Abstract][Full Text] [Related]
18. Intravenous infusion of iloprost and prostaglandin E1 (PGE1): cardiovascular profile in anaesthetized rabbits.
Müller B; Maass B; Stürzebecher S
Prog Clin Biol Res; 1989; 301():401-5. PubMed ID: 2477856
[No Abstract] [Full Text] [Related]
19. [Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible].
Melillo E; Nuti M; Buttitta F; Balbarini A
G Ital Cardiol (Rome); 2006 May; 7(5):317-35. PubMed ID: 16752515
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
Weiss T; Eckstein H; Weiss C; Diehm C
Vasc Med; 1998; 3(3):171-5. PubMed ID: 9892509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
